ObvioHealth and Oracle Announce Collaboration

Research shows GenAI has greater potential for a more immediate impact than previous digital technologies implemented in healthcare.

Jared Baeten, Vice President, Clinical Development, HIV Franchise Head at Gilead Sciences highlights how awareness and clinical innovation have transformed research in the HIV space.

Despite regulatory guidance, disability status is frequently unreported or overlooked in trial design.

Insightful sound bytes from KOLs attending SCOPE EUROPE 2023.

FDA grants to expedite review of zotatifin plus Faslodex (fulvestrant) and Verzenio (abemaciclib) for patients with ER–positive, HER2-negative advanced or metastatic breast cancer.

Included in the FDA warning were levetiracetam, under the brand names Keppra and Keppra XR; Elepsia XR; Spritam; and clobazam, under the brand names Onfi and Sympazan.